
The Creating and Restoring Equal Access to Equivalent Samples Act of 2017 aims to expedite the entry of lower-cost biosimilars and generics into the market.

The Creating and Restoring Equal Access to Equivalent Samples Act of 2017 aims to expedite the entry of lower-cost biosimilars and generics into the market.

Published: February 22nd 2019 | Updated: